Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program
September 27 2018 - 8:00AM
Business Wire
Newly manufactured plasmids will be applied in
clinical trials evaluating Oncoprex™ in combination with targeted
therapies and immunotherapies
Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene
therapy company developing a new approach to treating cancer based
upon a novel proprietary technology platform, has signed an
agreement with Aldevron, a leading contract manufacturing
organization, to supply TUSC2 (Tumor Suppressor Candidate2) plasmid
DNA for use in Genprex’s clinical development program evaluating
its immunogene therapy Oncoprex™ for the treatment of non-small
cell lung cancer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20180927005155/en/
“Plasmid DNA plays an important role in the delivery of gene
therapies into target cells,” said Rodney Varner, Chairman and
Chief Executive Officer of Genprex. “Aldevron is a leading plasmid
manufacturer that offers world-class laboratory and manufacturing
programs. Through this agreement, we have established a
GMP-validated supply of plasmid DNA vectors for our expanding
clinical program evaluating the utility of Oncoprex in combination
with some of the most promising new therapies for cancer.”
“Aldevron is honored to partner with Genprex in the development
of Oncoprex,” said Michael Chambers, CEO of Aldevron. “This
collaboration furthers our goal to provide high-quality plasmid DNA
and other biologics to leading companies such as Genprex that are
creating treatments that could have a significant impact on human
health.”
About Aldevron
Aldevron serves the biotechnology industry with custom
production of nucleic acids, proteins, and antibodies. Thousands of
clients use Aldevron-produced plasmids, RNA and gene editing
enzymes for projects ranging from discovery research to clinical
trials to commercial applications. These products are critical raw
materials and key components in commercially available drugs and
medical devices. Aldevron specializes in GMP manufacturing and is
known for inventing the GMP-SourceTM quality system. Company
headquarters are in Fargo, N.D., with additional facilities in
Madison, Wis., and Freiburg, Germany.
About Genprex™, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing a new approach to treating cancer, based upon a novel
proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex™ immunogene therapy for non-small cell
lung cancer (NSCLC). Genprex’s platform technologies are designed
to administer cancer fighting genes by encapsulating them into
nanoscale hollow spheres called nanovesicles, which are then
administered intravenously and taken up by tumor cells where they
express proteins that are missing or found in low quantities.
Oncoprex™ has a multimodal mechanism of action whereby it
interrupts cell signaling pathways that cause replication and
proliferation of cancer cells, re-establishes pathways for
apoptosis, or programmed cell death, in cancer cells, and modulates
the immune response against cancer cells. Oncoprex™ has also been
shown to block mechanisms that create drug resistance.
For more information, please
visit www.genprex.com or www.facebook.com/genprexinc.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of TUSC2 on cancer, the products and services we expect
to receive from Aldevron and the effect of those products and
services on the development of Oncoprex™. Risks that contribute to
the uncertain nature of the forward-looking statements include the
presence and level of TUSC2’s effect on cancer, Aldevron’s ability
to provide products and services to us and our ability to utilize
Aldevron’s products and services, the ability of Aldevron’s
products and services to influence the development of Oncoprex™, as
well as the timing and success of our clinical trials and planned
clinical trials of TUSC2 and Oncoprex™ and our other potential
product candidates and the timing and success of obtaining FDA
approval of Oncoprex™ and our other potential product candidates.
These and other risks and uncertainties are described more fully
under the caption "Risk Factors" and elsewhere in our filings and
reports with the United States Securities and Exchange Commission.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180927005155/en/
Media:ICR HealthcareJames Heins,
203-682-8251James.Heins@icrinc.comorAldevron Corporate
Development:James Brown, Ph.D.,
701-499-7330James.Brown@aldevron.comorInvestors:ICR
HealthcareStephanie Carrington,
646-277-1282Stephanie.Carrington@icrinc.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Sep 2023 to Sep 2024